Format

Send to

Choose Destination
Reprod Toxicol. 2016 Jul;62:87-91. doi: 10.1016/j.reprotox.2016.04.027. Epub 2016 May 2.

Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States.

Author information

1
University of California, Los Angeles, Department of Medicine, Los Angeles, CA, USA; Keck School of Medicine, University of Southern California, Department of Maternal-Fetal Medicine, Los Angeles, CA, USA. Electronic address: mfejzo@mednet.ucla.edu.
2
Hyperemesis Education and Research Foundation, Damascus, OR, USA.
3
Keck School of Medicine, University of Southern California, Department of Maternal-Fetal Medicine, Los Angeles, CA, USA.

Abstract

This is an analysis of fetal outcome in pregnancies exposed to ondansetron to treat Hyperemesis Gravidarum (HG). In this retrospective cohort study, U.S. data on outcome were collected on 1070 pregnancies exposed to ondansetron and compared to outcomes in two control groups: 771 pregnancies in women with a history of HG with no ondansetron exposure and 1555 pregnancies with neither a history of HG nor ondansetron exposure. Ventricular septal defects were reported in 2/952 of infants in the HG/Ondansetron-exposure group and 4/1286 in the No HG/No Ondansetron-exposure group. Cleft palate was reported in 1/952 live births in the HG/Ondansetron and 2/1286 in the No HG/No Ondansetron-exposure groups. Women with a history of HG who took ondansetron reported less miscarriages and terminations, and higher live birth rates. The overall results do not support evidence of teratogenicity of ondansetron.

KEYWORDS:

Birth defect; Cleft; Heart defect; Hyperemesis gravidarum; Morning sickness; Nausea; Ondansetron; Pregnancy

PMID:
27151373
DOI:
10.1016/j.reprotox.2016.04.027
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center